Following surgery, mice were housed individually with access to standard food and water
To qualify, besides having Medicare drug coverage, enrollees must have a body mass index of 35 or higher, or a BMI of 27 or higher alongside another health condition, such as a past heart attack or stroke, prediabetes or another from a list on the CMS website
Key results at the highest dose (24 mg): 22.5% placebo-adjusted mean weight loss at 48 weeks 96% achieved at least 5% weight loss 87% achieved at least 10% weight loss 48% achieved at least 20% weight loss 26% achieved at least 30% weight loss 54% reduced BMI below the obesity threshold (30 kg/m2) versus 13% placebo No weight loss plateau at 48 weeks Discontinuation due to adverse events: 5.9% (CT-388) vs 1.3% (placebo) Preclinical Data# CT-388 improved glycemic control in mice and monkeys, reduced body weight, suppressed appetite, and improved metabolic dysfunction-associated steatohepatitis (MASH) pathology in mice
Unlike fad diets or one-size-fits-all programs, medical weight loss is personalized, supervised, and based on science
From the widely-studied Semaglutide family (including research variants marketed as Ozempic, Wegovy, and Rybelsus) to earlier generation compounds like Exenatide and its extended-release variants, each offers unique characteristics for laboratory investigation
